Report Overview

The global Freidreichs Ataxia drugs market size is USD xx billion in 2019 and projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Friedreich ataxia is a rare inherited disease leading to progressive nervous system damage and issues in movement. The disease begins in childhood resulting into the impairment of muscle coordination that might get worse over time. It is caused by mutation in a gene labeled FXN. This gene carries the genetic code for a protein frataxin. Currently, there is no treatment for Friedreich ataxia; however, numerous drugs are in the pipeline and key players which will result in market growth in forecast period



Market Drivers

The global Friedreich ataxia management market is primarily driven by promising pipeline drugs targeting treatment for Friedreich ataxia, rise in awareness rare diseases, increase in geriatric population, and growing application of precision medicine in neurodegenerative diseases. Rise in research & development programs is also projected to boost the market during the forecast period